GSK Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de GSK de 21.9% y 3.9% por año respectivamente. Se prevé que el BPA crezca en un 21.7% al año. Se espera que la rentabilidad financiera sea de 28.7% en 3 años.

Información clave

21.9%

Tasa de crecimiento de los beneficios

21.7%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	23.7%
Tasa de crecimiento de los ingresos	3.9%
Rentabilidad financiera futura	28.7%
Cobertura de analistas	Good
Última actualización	18 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Previsiones de crecimiento de beneficios e ingresos

NYSE:GSK - Estimaciones futuras de los analistas y datos financieros pasados (GBP Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	34,338	6,520	6,489	9,537	16
12/31/2025	32,450	5,834	5,615	8,483	17
12/31/2024	31,271	3,802	3,962	6,617	17
9/30/2024	31,311	2,511	4,917	7,421	N/A
6/30/2024	31,446	4,033	5,222	7,479	N/A
3/31/2024	30,740	4,484	5,330	7,673	N/A
12/31/2023	30,328	4,928	4,436	6,768	N/A
9/30/2023	29,652	6,078	3,247	5,477	N/A
6/30/2023	29,334	5,373	2,486	4,586	N/A
3/31/2023	29,085	4,455	2,892	4,914	N/A
12/31/2022	29,324	4,461	5,341	7,403	N/A
9/30/2022	29,024	3,387	7,620	9,265	N/A
6/30/2022	27,822	3,505	8,073	10,506	N/A
3/31/2022	26,731	4,013	7,611	10,163	N/A
12/31/2021	24,696	3,316	5,939	7,952	N/A
9/30/2021	26,359	3,567	6,064	8,040	N/A
6/30/2021	28,378	3,934	4,871	6,339	N/A
3/31/2021	30,164	4,983	7,028	7,807	N/A
12/31/2020	24,354	4,873	6,839	8,441	N/A
9/30/2020	34,259	6,371	6,833	8,039	N/A
6/30/2020	34,998	6,679	8,751	9,693	N/A
3/31/2020	35,183	5,380	6,628	8,322	N/A
12/31/2019	33,754	4,645	6,261	8,020	N/A
9/30/2019	33,052	4,561	6,832	8,686	N/A
6/30/2019	31,759	4,427	6,488	8,248	N/A
3/31/2019	31,260	3,904	6,735	8,221	N/A
12/31/2018	30,821	3,623	6,881	8,421	N/A
9/30/2018	30,263	1,862	5,521	7,171	N/A
6/30/2018	30,014	1,656	N/A	6,991	N/A
3/31/2018	30,024	1,035	N/A	6,637	N/A
12/31/2017	30,186	1,532	N/A	6,918	N/A
9/30/2017	30,133	2,335	N/A	7,040	N/A
6/30/2017	29,832	1,931	N/A	6,910	N/A
3/31/2017	29,044	1,676	N/A	7,138	N/A
12/31/2016	27,889	912	N/A	6,497	N/A
9/30/2016	26,589	301	N/A	5,007	N/A
6/30/2016	25,174	31	N/A	3,721	N/A
3/31/2016	24,530	615	N/A	2,702	N/A
12/31/2015	23,923	8,422	N/A	2,569	N/A
9/30/2015	23,823	9,809	N/A	3,278	N/A
6/30/2015	23,342	9,672	N/A	4,070	N/A
3/31/2015	23,015	10,177	N/A	4,619	N/A
12/31/2014	23,006	2,756	N/A	5,176	N/A
9/30/2014	23,726	4,184	N/A	5,153	N/A
6/30/2014	24,590	4,752	N/A	5,957	N/A
3/31/2014	25,647	5,143	N/A	6,902	N/A
12/31/2013	26,505	5,436	N/A	7,222	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (21.9% al año) de GSK es superior a la tasa de ahorro (2.6%).

Beneficios vs. Mercado: Se prevé que los beneficios (21.9% al año) de GSK crezcan más rápidamente que el mercado US (15.4% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de GSK crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (3.9% al año) de GSK crezcan más despacio que el mercado de US (8.9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 3.9% al año) de GSK crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de GSK sea alta dentro de 3 años (28.7%)

GSK Crecimiento futuro

Future controles de criterios 4/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Linerixibat Shows Positive Phase III Results in Cholestatic Pruritus (Relentless Itch) in Primary Biliary Cholangitis (Pbc)

GSK plc Announces Overall Survival Results for Blenrep

GSK Q3 Earnings Preview: Shingrix And Arexvy Make The Stock A 'Strong Buy'

GSK plc Announces New Positive Arexvy Data in Younger Adults At Risk

GSK plc Announces US Food and Drug Administration Accepts New Drug Application for Treatment of Uncomplicated Urinary Tract Infections in Female Adults and Adolescents

GSK plc Announces Positive Headline Results from the Phase III Clinical Trials ANCHOR-1 and ANCHOR-2

Roche/Genentech's Gazyva Poised to Transform Lupus Nephritis Treatment After Positive Phase III Results

GSK plc Presents Positive Data for Arexvy, its Respiratory Syncytial Virus Vaccine

Gsk Plc's Menveomeningococcal Vaccine in New Single-Vial, Fully Liquid Presentation Receives Positive European Chmp Opinion

GSK plc Reaches Two Confidential Settlements in Cases Filed in California State Court with John Russell

GSK plc Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX

GSK plc Announces Positive Headline Results of A Phase Ii Trial (Nct06431607) for Its Mrna Seasonal Influenza Vaccine Programme

GSK plc Reaches Confidential Settlement in Zantac Litigation with Isaac Dixon

GSK plc Provides Update on Phase I/II Therapeutic Herpes Simplex Virus Vaccine Trial

GSK plc Announces European Commission Has Authorised Arexvy for Active Immunisation for the Prevention of Lower Respiratory Tract Disease

GSK plc Announces Zantac (Ranitidine) Litigation Update

GSK's Q2 Success Amid Challenges: What Investors Need To Know

GSK plc Receives US Food and Drug Administration Breakthrough Therapy Designation for GSK5764227

Gsk plc Announces Zantac (Ranitidine) Litigation Update

GSK plc Announces Zantac (Ranitidine) Litigation Update

GSK plc Announces US FDA Expands Jemperli (Dostarlimab-Gxly) Plus Chemotherapy Approval to All Adult Patients with Primary Advanced or Recurrent Endometrial Cancer as the First and Only Immuno-Oncology-Based Treatment to Show an Overall Survival Benefit

GSK: Good Earnings Report, But Risks Ahead (Rating Downgrade)

GSK plc Declares Second Interim Dividend for Second Quarter of 2024, Payable on 10 October 2024

GSK plc Announces Blenrep EMA Filing Acceptance

GSK plc Begins Shipping Influenza Vaccine Doses for 2024-25 Season

GSK's Omjjara (Momelotinib) Receives Approval in Japan for Treatment of Myelofibrosis

iTeos Therapeutics, Inc. and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer

GSK plc Announces That the US Food and Drug Administration (FDA) Has Approved Arexvy

GSK plc (LSE:GSK) acquired Elsie Biotechnologies for $50 million.

GSK plc Announces Positive Results from an Interim Analysis of the DREAMM-8 Phase III Head-To-Head Trial Evaluating Belantamab Mafodotin

GSK plc Provides Litigation Update

GSK Breathes New Life Into Asthma Treatment With Depemokimab

An unknown buyer intended to acquire 4.2% stake in Haleon plc (LSE:HLN) from GSK plc (LSE:GSK) for £1.2 billion.

GSK Announces Intention to Sell Approximately 385 Million Shares in Haleon

Gsk plc Announces Board Committee Changes

GSK plc to Report Q2, 2024 Results on Jul 31, 2024

GSK plc Announces the US Food and Drug Administration Accepted the Supplemental Biologics License Application for Jemperli

GSK plc Announces Positive Results from the Pivotal Eagle-1 Phase III Trial for Gepotidacin

GSK plc Announces US Food and Drug Administration Accepts for Review Biologics License Application for its 5-in-1 Meningococcal ABCWY (MenABCWY) Vaccine Candidate

GSK plc, Annual General Meeting, May 08, 2024

GSK plc Appoints Hal Dietz as Member of Nominations & Corporate Governance Committee, Effective 11 March 2024

GSK plc Announces Positive Headline Results from an Interim Analysis of the Dreamm-8 Phase Iii Head-To-Head Trial Evaluating Blenrep (Belantamab Mafodotin)

GSK plc Reaches a Confidential Settlement with Boyd/Steenvoord

GSK plc (LSE:GSK) completed the acquisition of Aiolos Bio, Inc. from a group of shareholders.

GSK plc Receives US Food and Drug Administration Fast Track Designation for Bepirovirsen in Chronic Hepatitis B

Center for Drug Evaluation Accepts to Review GSK's Regulatory Application for Shingrix for the Prevention of Shingles in at-Risk Adults Aged 18 and over

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento